NEW MJ NEWS

Jushi Holdings Inc. to Report Third Quarter 2022 Financial Results on November 14, 2022

Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF), a vertically integrated, multi-state cannabis operator, announced that it expects to report its financial results for the third quarter ended September 30, 2022, before the market opens on Monday, November 14, 2022.

Management will host a conference call and audio webcast that morning at 9:00 a.m. ET to discuss the Company’s financial results.

Event:

Third Quarter 2022 Financial Results Conference Call

Date:

Monday, November 14, 2022

Time:

9:00 a.m. Eastern Time

Live Call:

1-866-374-5140 (U.S. Toll-Free) / 1-866-455-3403 (Canada Toll-Free)

Conference ID

42084746#

Webcast:

Register

For interested individuals unable to join the conference call, a webcast of the call will be available for one year following the conference call and can be accessed via webcast on Jushi’s Investor Relations website.

About Jushi Holdings Inc.
We are a vertically integrated cannabis company led by an industry-leading management team. In the United States, Jushi is focused on building a multi-state portfolio of branded cannabis assets through opportunistic acquisitions, distressed workouts, and competitive applications. Jushi strives to maximize shareholder value while delivering high-quality products across all levels of the cannabis ecosystem. For more information, visit jushico.com or our social media channels, Instagram, Facebook, Twitter, and LinkedIn.

For further information, please contact:

Investor Relations
Michael Perlman
Executive Vice President of Investor Relations
Investors@jushico.com
(561) 281-0247

Media Contact
Ellen Mellody
MATTIO Communications
Ellen@Mattio.com
(570) 209-2947


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

$CARA Top-Line Results From Phase 2a Trial of Oral CR845

Top-Line Results From Phase 2a Trial of Oral CR845 in Chronic Pain…

4Front Ventures Corp. (FFNT) (FFNTF) to open for adult-use sales at its Chicago dispensary

4Front to open for adult-use sales at its Chicago dispensary  4Front Ventures…

Cara Therapeutics, Inc. (CARA) Announces Positive Results From KALM-1 Pivotal Phase 3 Trial of KORSUVA™

Cara Therapeutics Announces Positive Results From KALM-1 Pivotal Phase 3 Trial of…